The Firm represented PPL Corporation (“PPL”) and PPL Capital Funding, Inc. (“PPL Capital Funding”) in the remarketing of $1.15 billion of junior subordinated notes (the “junior notes”) of PPL Capital Funding related to the equity units originally issued by PPL in June 2010. In connection with the remarketing, PPL Capital Funding issued $250 million 1.90% Senior Notes due 2018, $600 million 3.40% Senior Notes due 2023 and $300 million 4.70% Senior Notes due 2043 (collectively, the “senior notes”), which were sold to the purchasers of the junior notes (the “purchasers”) in exchange for the junior notes. The senior notes were sold by the purchasers in an SEC-registered secondary offering, managed by Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, RBS Securities Inc. and Wells Fargo Securities, LLC.

More >>

The Firm recently represented the initial purchasers in connection with Cinemark USA, Inc.’s private placement of $530 million aggregate principal amount of 4.875% Senior Notes due 2023. Barclays Capital Inc., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and Wells Fargo Securities LLC acted as joint book-running managers in connection with the senior notes offering. Cinemark USA, Inc. intends to use the net proceeds from the senior notes offering, together with cash on hand, to redeem all of its outstanding 8.625% Senior Notes due 2019 and for fees and expenses related to the refinancing transactions.

More >>

The Firm is representing funds advised by Apax Partners in connection with the announced acquisition of all outstanding shares of rue21, Inc. (Nasdaq: RUE) for approximately $1.1 billion, including the assumption of debt. Approximately 30% of the outstanding shares of rue21 are collectively owned by SKM II funds. The transaction is expected to close before the end of the year and is subject to approval by the majority of the stockholders unaffiliated with the SKM II funds as well as customary closing conditions.

More >>

Xellia Pharmaceuticals, a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, announced that Novo A/S, the holding company of the Novo Group, has entered into an agreement to purchase all shares of the group for approximately US $700 million from 3i and other current shareholders, as detailed in the company press release below. Closing of the transaction will be subject to relevant competition law approvals, and is expected to take place during the third quarter of 2013.

More >>

Cahill represented Morgan Stanley as administrative agent and Morgan Stanley and Jefferies as arrangers in connection with the $240,000,000 Term B Loan for Alvogen Pharma US, Inc. Proceeds from the loan will be used for general corporate purposes and to refinance existing indebtedness.

More >>